Skip to main content
. 2023 Aug 2;29(1):e97–e107. doi: 10.1093/oncolo/oyad220

Figure 2.

Figure 2.

ROC curve analysis assessing the ability of ETS to predict PFS at 12 weeks and OS at 36 weeks in the GC and GS arms. (A) Time-dependent ROC curve for PFS at 12 weeks in the GC arm. (B) Time-dependent ROC curve for PFS at 12 weeks in the GS arm. (C) Time-dependent ROC curve for OS at 36 weeks in the GC arm. (D) Time-dependent ROC curve for OS at 36 weeks in the GS arm. Abbreviations: PFS: progression-free survival; OS: overall survival; ETS: early tumor shrinkage; GC: gemcitabine plus cisplatin; GS: gemcitabine plus S-1; ROC: receiver operating characteristic; AUC: area under the curve.